Administered by the United States Patent and Trademark Office (USPTO) and regulated under
35 U.S.C. § 101 and § 120, the U.S. patent system strictly prohibits double patenting, a
statutory rule designed to prevent unreasonable extension of patent protection through
multiple overlapping patents. When an applicant files a subsequent patent application that
contains claims substantially identical or non-distinctively different from a previously granted
parent patent, USPTO examiners will issue a double patenting rejection. The only routine
remedy to overcome such rejections is submitting aTerminal Disclaimer (TD), a legally binding
declaration that limits the term of the new patent to expire concurrently with the parent patent.
This 2026 case study focuses on a typical double patenting rejection and terminal disclaimer
remedy, clarifying compliance rules and risk avoidance strategies for global R&D enterprises
with continuous iterative patent filings.
Case Overview: Double Patenting Rejection and Terminal Disclaimer Remedy
A professional industrial automation technology enterprise with continuous R&D capabilities
filed a core mechanical structure invention patent with USPTO in 2018, obtaining formal
authorization in 2020 with a 20-year protection term calculated from the original filing date.
During subsequent product iteration and technical upgrading, the company optimized partial
structural parameters and assembly processes of the original invention, and submitted a new
continuation-in-part patent application in 2022, aiming to protect upgraded technical solutions
and expand claim coverage.
In the 2024 substantive examination stage, USPTO issued an official non-statutory double patenting
rejection. The examiner confirmed that the improved technical solution did not form a substantial
inventive leap compared with the parent patent, and the core functional claims lacked distinct
technical differences, which would lead to repeated and prolonged monopolistic protection of the
same technical principle. Without effective remedial measures, the subsequent application would
be completely rejected. To save the valid technical solution and obtain stable patent rights, the
enterprise entrusted a professional IP team to study the case and finally submitted a standard
terminal disclaimer document in accordance with USPTO specifications.
The submitted terminal disclaimer clearly stipulated that the term of the new patent would terminate
simultaneously with the expiration of the 2018 parent patent, voluntarily abandoning the right to
extended protection. After verifying the validity of the disclaimer document and confirming no
illegal term extension risk, USPTO withdrew the double patenting rejection and granted the new
patent in early 2025. Although the valid protection period of the new patent was shortened, the
enterprise successfully obtained exclusive rights for the upgraded technology and avoided
complete loss of the iterative R&D achievements.
Core Legal and Procedural Insights
First, double patenting prohibition applies to iterative and continuous patent filings. USPTO strictly
restricts repeated authorization of similar technical solutions derived from the same core principle,
whether through divisional applications, continuation applications, or improved supplementary
filings. Substantively overlapping claims will inevitably trigger double patenting examination
objections.
Second, terminal disclaimer is the only effective remedy for most non-statutory double patenting
rejections. This legal instrument requires applicants to waive extended patent terms unconditionally,
ensuring all overlapping patents derived from the same technical basis maintain consistent
expiration dates and comply with U.S. patent public policy and fair competition rules.
Third, terminal disclaimer records have permanent legal binding force. Once filed and approved, the
term restriction cannot be revoked or modified in subsequent stages including patent maintenance,
litigation and rights enforcement. The waived extended protection rights are permanently invalid.
Fourth, terminal disclaimer does not affect independent enforcement rights of each patent. Although
the terms are unified, both parent and subsequent patents can independently initiate infringement
lawsuits, claim damages and conduct licensing operations during the valid period, retaining
complete commercial value of iterative patents.
Practical Compliance Guidance for Global Enterprises
Global tech enterprises conducting iterative R&D and continuous patent layout must establish
standardized pre-filing risk assessment mechanisms. Before submitting improved or continued
applications, teams need to compare claim differences with existing authorized patents to judge
whether there are substantial overlapping risks and predict double patenting rejection probability
in advance.
Enterprises should distinguish substantial innovative improvement from routine technical
optimization. Solutions with prominent inventive steps and obvious technical breakthroughs can
overcome double patenting rejections through argumentation, while minor iterative optimizations
need to reserve terminal disclaimer remedy plans in advance.
Hyperlink List：
● IPcrossark:
